Comparative Pharmacology
Head-to-head clinical analysis: TZ 3 versus WIDAPLIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TZ 3 versus WIDAPLIK.
TZ-3 vs WIDAPLIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
(S)-3-(4-(2-((3-fluorophenyl)amino)-2-oxoethyl)piperazin-1-yl)-N,N-dimethylpropanamide; selectively inhibits the interaction between the PD-1/PD-L1 immune checkpoint, blocking the PD-1/PD-L1 pathway and restoring antitumor T-cell function.
WIDAPLIK is a small-molecule inhibitor of cyclin-dependent kinase 12 (CDK12). By selectively inhibiting CDK12, it interferes with the phosphorylation of RNA polymerase II, leading to reduced expression of DNA damage response genes and promoting apoptosis in cancer cells.
100 mg orally twice daily
50 mg orally twice daily.
None Documented
None Documented
12–18 hours (terminal). Steady-state achieved in ~3 days. Extended to ~30 hours in severe renal impairment.
Terminal elimination half-life is 12 hours (range 10–14 h) in healthy adults; prolonged to 24–36 h in moderate renal impairment (CrCl 30–50 mL/min).
Primarily renal (60–70% unchanged), with 20–30% biliary/fecal, and <10% metabolized. Dosage adjustment required in renal impairment.
Primarily renal excretion as unchanged drug (approximately 70%) with 20% as inactive metabolites; 10% via feces.
Category C
Category C
Unknown
Unknown